JPWO2020118094A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020118094A5
JPWO2020118094A5 JP2021532126A JP2021532126A JPWO2020118094A5 JP WO2020118094 A5 JPWO2020118094 A5 JP WO2020118094A5 JP 2021532126 A JP2021532126 A JP 2021532126A JP 2021532126 A JP2021532126 A JP 2021532126A JP WO2020118094 A5 JPWO2020118094 A5 JP WO2020118094A5
Authority
JP
Japan
Prior art keywords
seq
region
cell
tcr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512326A (ja
JP2022512326A5 (https=
JP7571021B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064757 external-priority patent/WO2020118094A1/en
Publication of JP2022512326A publication Critical patent/JP2022512326A/ja
Publication of JP2022512326A5 publication Critical patent/JP2022512326A5/ja
Publication of JPWO2020118094A5 publication Critical patent/JPWO2020118094A5/ja
Application granted granted Critical
Publication of JP7571021B2 publication Critical patent/JP7571021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532126A 2018-12-06 2019-12-05 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 Active JP7571021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776012P 2018-12-06 2018-12-06
US62/776,012 2018-12-06
PCT/US2019/064757 WO2020118094A1 (en) 2018-12-06 2019-12-05 Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints

Publications (4)

Publication Number Publication Date
JP2022512326A JP2022512326A (ja) 2022-02-03
JP2022512326A5 JP2022512326A5 (https=) 2022-12-09
JPWO2020118094A5 true JPWO2020118094A5 (https=) 2022-12-09
JP7571021B2 JP7571021B2 (ja) 2024-10-22

Family

ID=70974859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532126A Active JP7571021B2 (ja) 2018-12-06 2019-12-05 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法

Country Status (7)

Country Link
US (2) US20210369776A1 (https=)
JP (1) JP7571021B2 (https=)
KR (1) KR20210112310A (https=)
CN (1) CN113226335B (https=)
SG (1) SG11202105975SA (https=)
TW (1) TW202039545A (https=)
WO (1) WO2020118094A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014285A2 (en) 2018-07-09 2020-01-16 Intrexon Corporation Fusion constructs and methods of using thereof
CN111718409B (zh) * 2020-06-17 2021-03-02 深圳豪石生物科技有限公司 一种t细胞受体及其应用
EP4178680A4 (en) * 2020-07-10 2024-07-31 Precigen, Inc. FUSION CONSTRUCTS AND THEIR METHODS OF USE
CN112940108B (zh) * 2021-03-19 2022-10-14 河南省肿瘤医院 识别ebv抗原的t细胞受体以及该t细胞受体的应用
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
CN116179493A (zh) * 2021-09-29 2023-05-30 成都美杰赛尔生物科技有限公司 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用
US20260078163A1 (en) * 2022-09-06 2026-03-19 Board Of Regents, The University Of Texas System T-cell receptor that targets egfr mutation and methods of using the same
WO2024173916A1 (en) * 2023-02-17 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods of preventing t cell exhaustion
CN119390814B (zh) * 2023-10-26 2025-06-27 上海市第一人民医院 一种t细胞受体及其制备方法和用途
CN119978143B (zh) * 2025-01-26 2025-10-21 湖南大学 一种基于synNotch的工程化巨噬细胞及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002941A1 (en) * 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) * 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017040945A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
KR20190003938A (ko) * 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
US11549099B2 (en) * 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
US12060394B2 (en) * 2016-04-28 2024-08-13 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
WO2018162563A1 (en) * 2017-03-07 2018-09-13 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
AU2018254517A1 (en) * 2017-04-19 2019-12-05 University Of Southern California Compositions and methods for treating cancer
JP7340458B2 (ja) * 2017-05-09 2023-09-07 アメリカ合衆国 Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ

Similar Documents

Publication Publication Date Title
CN109485734B (zh) 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
CN109306005B (zh) 一种eb病毒特异性t细胞抗原受体及其应用
CN103483452B (zh) 双信号独立的嵌合抗原受体及其用途
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
JP2020096630A5 (https=)
CN110615843B (zh) 一种包含第三信号受体的嵌合抗原受体及其应用
CN110357953B (zh) 识别人巨细胞病毒pp65抗原的TCR
CN110357952B (zh) 识别人乳头瘤病毒hpv16-e7抗原的tcr
CN106046162B (zh) 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用
JP2019519245A5 (https=)
CN102702358A (zh) 针对csf-1r的抗体
CN112480239B (zh) 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途
CN111925451B (zh) 一种靶向bcma的嵌合抗原受体(car)及其应用
JPWO2020118094A5 (https=)
RU2013106217A (ru) Гибридный белок из антитела против мнс и противовирусного цитокина
CN110423757B (zh) 一种工程化核酸、t细胞及其应用和产生方法
SK285169B6 (sk) Sekvencie nukleových kyselín, vektory tieto sekvencie nukleových kyselín obsahujúce, farmaceutické kompozície a ich terapeutické použitie
CN111944054A (zh) 抗bcma的car及其表达载体和应用
US20200215112A1 (en) Chimeric antigen receptor for her2/neu and t-cells expressing same
CN117186229A (zh) 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用
CN117069844B (zh) 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
Perera Molligoda Arachchige NK cell-based therapies for HIV infection: Investigating current advances and future possibilities
CN112996909A (zh) 表达pd-1结合蛋白的溶瘤病毒及其应用
CN111944053A (zh) 抗bcma的car及其表达载体和应用
EP3816190B1 (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof